Balyasny Asset Management
DNLI icon

Balyasny Asset Management’s Denali Therapeutics DNLI Stock Holding History

Balyasny Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-195,108
Closed -$4.01M – 3110
2026
Q1 		$3.75M Buy
+195,108
New +$3.88M ﹤0.01% 1498
2025
Q2 		– Sell
-16,595
Closed -$226K – 2940
2025
Q1 		$226K Sell
16,595
-399,479
-96% -$7.65M ﹤0.01% 2546
2024
Q4 		$8.48M Buy
416,074
+370,966
+822% +$9.5M 0.01% 1037
2024
Q3 		$1.31M Sell
45,108
-75,504
-63% -$1.87M ﹤0.01% 1855
2024
Q2 		$2.8M Sell
120,612
-242,415
-67% -$4.65M ﹤0.01% 1414
2024
Q1 		$7.45M Buy
363,027
+102,440
+39% +$1.93M 0.01% 1062
2023
Q4 		$5.59M Buy
+260,587
New +$5.16M 0.01% 1079
2023
Q1 		– Sell
-1,313
Closed -$36.5K – 2760
2022
Q4 		$36.5K Buy
+1,313
New +$39.1K ﹤0.01% 2397
2022
Q1 		– Sell
-12,874
Closed -$574K – 2547
2021
Q4 		$574K Buy
12,874
+6,510
+102% +$308K ﹤0.01% 1591
2021
Q3 		$321K Sell
6,364
-95,570
-94% -$5.39M ﹤0.01% 1574
2021
Q2 		$8M Buy
101,934
+33,832
+50% +$2.09M 0.04% 575
2021
Q1 		$3.89M Buy
68,102
+18,028
+36% +$1.21M 0.02% 784
2020
Q4 		$4.19M Sell
50,074
-13,886
-22% -$839K 0.02% 698
2020
Q3 		$2.29M Buy
+63,960
New +$1.93M 0.02% 800
2020
Q2 		– Sell
-54,266
Closed -$950K – 1198
2020
Q1 		$950K Buy
+54,266
New +$1.13M 0.01% 772
2019
Q3 		– Sell
-120,402
Closed -$2.5M – 1264
2019
Q2 		$2.5M Buy
+120,402
New +$2.7M 0.02% 811

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Balyasny Asset Management's DNLI Position: Q2 2026 in Review

Balyasny Asset Management sold out of Denali Therapeutics (DNLI) in Q2 2026, closing a stake of 195,108 shares — an estimated $4.01M sold.

Balyasny Asset Management first reported a position in DNLI in Q2 2019 and held it in 16 quarters. The position peaked at $8.48M in Q4 2024. 293 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Balyasny Asset Management reported no remaining Denali Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 195,108 Denali Therapeutics shares in Q2 2026, an estimated $4.01M.
  • Balyasny Asset Management first reported a position in Denali Therapeutics in Q2 2019 and held it in 16 quarters.
  • Balyasny Asset Management's Denali Therapeutics position peaked at $8.48M in Q4 2024.
  • 293 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.